摘要
目的探讨氯沙坦联合吲哒帕胺对老年高血压患者的血压、血尿酸(UA)及血、尿β2-微球蛋白(β2-MG)的影响。方法50例老年高血压患者随机分成两组,对照组(吲哒帕胺组)24例,观察组(氯沙坦加吲哒帕胺组)26例,观察12 w,比较治疗前后患者血压、血钾、血UA及血、尿β2-MG等指标的变化。结果治疗后两组收缩压及舒张压均较治疗前明显下降(P<0.01),两组比较无差异(P>0.05);对照组治疗前后比较,血UA浓度明显升高(P<0.01),血、尿β2-MG浓度无明显变化,血钾明显降低(P<0.05),观察组治疗前后血UA及血、尿β2-MG均明显下降(P<0.01)。结论吲哒帕胺和氯沙坦联合治疗老年高血压病,较单独用药更有效地控制血压,降低血UA及减少低血钾的发生,保护靶器官,具有良好的安全性和耐受性。
Objective To evaluate the therapeutic effect and safety of the blood pressure-independent role of valsartan on the patients with type 2 diabetic mellitus （T2DM） with microalbuminuria （MAU）. Methods 137 patients with T2DM and MAU complicating with or without hypertension, were randomly assigned to valsartan group or amlodipine group, period of treatment as 12 weeks. A target blood pressure （BP） was 135/85 mmHg. Urinary albumin excretion rate （UAER） and BP in two groups were determined before and after treatment. Results The UAER at 12 week in valsartan group and amlodipine group reduced 56% and 92% , there was significant difference between two groups （P 〈 0. 001 ）. Valsartan lowered similarly UAER in both the hypertensive and normotensive subgroups without significant changes before and after treatment （P 〉0.05 ）. For the same level of attained BP reduction,valsartan lowered UAER more effectively than amlodipine, Conclusions Valsartan could play BP-independent reductive MAU role in patients with diabetic nephropathy.
出处
《中国老年学杂志》
CAS
CSCD
北大核心
2005年第9期1023-1024,共2页
Chinese Journal of Gerontology
关键词
老年高血压
吲哒帕胺
氯沙坦
尿酸
Β2-微球蛋白
Diabetic nephropathy
Blood pressure
Valsartan
Urinary albumin excretion rate （UAER）
